Sign In

Login

Password

Forgot Password ? Sign Up

Cariprazin (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cariprazin" in German language version.

refsWebsite
Global rank German rank
9nih.gov
4th place
7th place
8doi.org
2nd place
3rd place
3gelbe-liste.de
low place
2,430th place
2europa.eu
68th place
29th place
1cas.org
8,332nd place
1,213th place
1chemspider.com
8,573rd place
1,211th place
1drugbank.ca
4,294th place
2,006th place
1wikidata.org
43rd place
985th place
1aerztezeitung.de
low place
711th place
1g-ba.de
low place
1,618th place
1web.archive.org
1st place
1st place

aerztezeitung.de

cas.org

commonchemistry.cas.org

chemspider.com

doi.org

  • Leslie Citrome: Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. In: Expert Opinion on Drug Metabolism & Toxicology. Band 9, Nr. 2, 2013, S. 193–206, doi:10.1517/17425255.2013.759211, PMID 23320989.
  • Suresh Durgam et al.: An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. In: Schizophrenia Research. Band 152, Nr. 2, 2014, S. 450–457, doi:10.1016/j.schres.2013.11.041, PMID 24412468.
  • Suresh Durgam et al.: Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial. In: The Journal of Clinical Psychiatry. Band 76, Nr. 12, 2015, S. 1574–1582, doi:10.4088/jcp.15m09997, PMID 26717533.
  • John M. Kane et al.: Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial. In: Journal of Clinical Psychopharmacology. Band 35, Nr. 4, 2015, S. 367–373, doi:10.1097/jcp.0000000000000346, PMID 26075487.
  • Suresh Durgam et al.: Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. In: Schizophrenia Research. Band 176, Nr. 2, 2016, S. 264–271, doi:10.1016/j.schres.2016.06.030, PMID 27427558.
  • György Németh et al.: Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. In: The Lancet. Band 389, Nr. 10074, 2017, S. 1103–1113, doi:10.1016/s0140-6736(17)30060-0, PMID 28185672.
  • Bela Kiss et al.: Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile. In: Journal of Pharmacology and Experimental Therapeutics. Band 333, Nr. 1, 2010, S. 328–340, doi:10.1124/jpet.109.160432, PMID 20093397.
  • Ragy R. Girgis et al.: Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. In: Psychopharmacology. Band 233, Nr. 19, 2016, S. 3503–3512, doi:10.1007/s00213-016-4382-y, PMID 27525990.

drugbank.ca

europa.eu

echa.europa.eu

ema.europa.eu

g-ba.de

gelbe-liste.de

nih.gov

ncbi.nlm.nih.gov

  • Leslie Citrome: Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. In: Expert Opinion on Drug Metabolism & Toxicology. Band 9, Nr. 2, 2013, S. 193–206, doi:10.1517/17425255.2013.759211, PMID 23320989.
  • Suresh Durgam et al.: An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. In: Schizophrenia Research. Band 152, Nr. 2, 2014, S. 450–457, doi:10.1016/j.schres.2013.11.041, PMID 24412468.
  • Suresh Durgam et al.: Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial. In: The Journal of Clinical Psychiatry. Band 76, Nr. 12, 2015, S. 1574–1582, doi:10.4088/jcp.15m09997, PMID 26717533.
  • John M. Kane et al.: Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial. In: Journal of Clinical Psychopharmacology. Band 35, Nr. 4, 2015, S. 367–373, doi:10.1097/jcp.0000000000000346, PMID 26075487.
  • Suresh Durgam et al.: Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. In: Schizophrenia Research. Band 176, Nr. 2, 2016, S. 264–271, doi:10.1016/j.schres.2016.06.030, PMID 27427558.
  • György Németh et al.: Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. In: The Lancet. Band 389, Nr. 10074, 2017, S. 1103–1113, doi:10.1016/s0140-6736(17)30060-0, PMID 28185672.
  • Bela Kiss et al.: Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile. In: Journal of Pharmacology and Experimental Therapeutics. Band 333, Nr. 1, 2010, S. 328–340, doi:10.1124/jpet.109.160432, PMID 20093397.
  • Ragy R. Girgis et al.: Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. In: Psychopharmacology. Band 233, Nr. 19, 2016, S. 3503–3512, doi:10.1007/s00213-016-4382-y, PMID 27525990.

pubchem.ncbi.nlm.nih.gov

web.archive.org

wikidata.org